Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Meta-Analysis
. 2022 Feb;88(2):441-451.
doi: 10.1111/bcp.14943. Epub 2021 Jun 28.

Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis

Daniele Pastori  1 , Arianna Pani  2 , Arianna Di Rocco  3 , Danilo Menichelli  1 , Gianluca Gazzaniga  2 , Alessio Farcomeni  4 , Laura D'Erasmo  5 , Francesco Angelico  3 , Maria Del Ben  1 , Francesco Baratta  1
Affiliations
Meta-Analysis

Statin liver safety in non-alcoholic fatty liver disease: A systematic review and metanalysis

Daniele Pastori et al. Br J Clin Pharmacol. 2022 Feb.

Abstract

Aims: Statin liver safety in non-alcoholic fatty liver disease (NAFLD) patients is not well defined. We analysed differences in liver function tests, including alanine transaminase aminotransferase (ALT), aspartate transaminase (AST) and gamma-glutamyl transpeptidase (GGT) in NAFLD patients treated or not treated with statins.

Methods: We performed a systematic review of MEDLINE via PubMed and EMBASE databases and metanalysis of clinical studies investigating levels of ALT, AST and GGT in NAFLD according to statin treatment. Mean difference (MD) and percentage MD were calculated between the two groups.

Results: We included 22 studies with 2345 NAFLD patients. Overall, 16 were before-after interventional, five were cross-sectional and one was combined cross-sectional/interventional study. In all interventional studies, except one, patients had raised ALT, AST and GGT at baseline. Interventional studies showed reduced ALT values with an MD reduction of -27.2 U/L (95% CI -35.25/-19.15) and a percentage MD reduction of -35.41% (95% CI -44.78/-26.04). Also, AST values were reduced after statin treatment in interventional studies with an MD of -18.82 U/L (95% CI -25.63/-12.02) (percentage -31.78%, 95% CI -41.45/-22.11). Similarly, GGT levels were reduced after statin treatment with an MD of -19.93 U/L (95% CI -27.10/-12.77) (percentage -25.57%, 95% CI -35.18/-15.97). Cross-sectional studies showed no difference in AST and GGT values between patients treated with and without statins.

Conclusion: In interventional studies, ALT, AST and GGT were reduced after statin treatment with a percentage mean difference of -35.41%, -31.78% and -25.57%, respectively, while observational studies showed a null effect, suggesting liver safety of statins in NAFLD patients.

Keywords: ALT; AST; GGT; NAFLD; liver; safety; statins.

PubMed Disclaimer

Figures

FIGURE 1
FIGURE 1
The Risk of Bias Assessment tool for Non‐randomized Studies (RoBANS) (red: high risk; yellow: unclear risk; green: low risk)
FIGURE 2
FIGURE 2
Changes in ALT levels (mean difference, Panel A; percentual difference, Panel B) according to statin treatment
FIGURE 3
FIGURE 3
Changes in AST levels (mean difference, Panel A; percentual difference, Panel B) according to statin treatment
FIGURE 4
FIGURE 4
Changes in GGT levels (mean difference, Panel A; percentual difference, Panel B) according to statin treatment
See this image and copyright information in PMC

References

    1. Younossi Z, Anstee QM, Marietti M, et al. Global burden of NAFLD and NASH: trends, predictions, risk factors and prevention. Nat Rev Gastroenterol Hepatol. 2018;15(1):11‐20. - PubMed
    1. Wong RJ, Aguilar M, Cheung R, et al. Nonalcoholic steatohepatitis is the second leading etiology of liver disease among adults awaiting liver transplantation in the United States. Gastroenterology. 2015;148(3):547‐555. - PubMed
    1. Angelico F, Del Ben M, Conti R, et al. Non‐alcoholic fatty liver syndrome: a hepatic consequence of common metabolic diseases. J Gastroenterol Hepatol. 2003;18(5):588‐594. - PubMed
    1. Käräjämäki AJ, Bloigu R, Kauma H, et al. Non‐alcoholic fatty liver disease with and without metabolic syndrome: different long‐term outcomes. Metabolism. 2017;66:55‐63. - PubMed
    1. Stahl EP, Dhindsa DS, Lee SK, Sandesara PB, Chalasani NP, Sperling LS. Nonalcoholic fatty liver disease and the heart: JACC state‐of‐the‐art review. J Am Coll Cardiol. 2019;73(8):948‐963. - PubMed

MeSH terms

Substances